{"id":54861,"date":"2026-10-29T14:23:28","date_gmt":"2026-10-29T14:23:28","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=54861"},"modified":"2026-10-29T17:57:20","modified_gmt":"2026-10-29T17:57:20","slug":"avac-focus-on-global-access-to-lenacapavir-prep","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/54861","title":{"rendered":"AVAC reports calls for increased global access to lenacapavir PrEP"},"content":{"rendered":"

Simon collins, HIV i-Base<\/strong><\/p>\n

On 21 October 2026, AVAC published a new analysis calling for a minimum target of 3 million people to have access to injectable lenacapavir PrEP globally by then end of 2027. [1]<\/strong><\/p>\n

The analysis, published as a 7-page report titled Now What with Injectable LEN for PrEP<\/a> outlines options for more ambitious country forecasts to accelerate access to generics, the first of which should become available by the end of 2026.<\/p>\n

It proposes two scenarios that model expanding production including the capacity for Gilead and generic manufacturers to meet greater demand. It also includes the market impact of this investment going forward in 2028. including the potential to drive generic prices lower.<\/p>\n

comment<\/h3>\n

Currently there is very little access to lenacapavir PrEP in any country.<\/strong><\/p>\n

This includes the UK, Europe, Australia and other high-income countries when the US price will never prove cost-effective for public health access.<\/strong><\/p>\n

While community activism is focussed on achieving a lower price for lenacapavir PrEP, it is also possible that Gilead has little interest in UK and EU access because it would destabilise their HIV treatment market centred on US pricing.<\/strong><\/h3>\n

Although the report notes that the infrastructure being developed for injectable PrEP will prepare for the potential introductions of monthly oral PrEP if the phase 3 studies of alimatravir show high efficacy, the expected lower costs from manufacturing and distributing 12 pills is always likely to be significantly cheaper than any injectable. [2]<\/strong><\/p>\n

References<\/p>\n

    \n
  1. AVAC and Access Bridge. Now What with Injectable LEN for PrEP. (21 October 2026.
    \n    https:\/\/avac.org\/resource\/now-what-with-injectable-len-for-prep<\/a> (web page)
    \n    https:\/\/avac.org\/wp-content\/uploads\/2025\/07\/Now_What_LEN_Oct2026.pdf<\/a> (PDF)<\/li>\n
  2. \n

    Merck announces alimatravir access programme ahead of AIDS 2026. HTB (24 July 2026).
    \n    https:\/\/i-base.info\/htb\/54297<\/a><\/p>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon collins, HIV i-Base On 21 October 2026, AVAC published a new analysis calling for a minimum target of 3 million people to have access to injectable lenacapavir PrEP globally by then end of 2027. [1] The analysis, published as …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,30],"tags":[],"class_list":["post-54861","post","type-post","status-publish","format-standard","hentry","category-transmission-and-prevention","category-on-the-web"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/54861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=54861"}],"version-history":[{"count":5,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/54861\/revisions"}],"predecessor-version":[{"id":54867,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/54861\/revisions\/54867"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=54861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=54861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=54861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}